Potential of Allospecific Gene-Engineered T Cells in Transplantation Gene Therapy: Specific T Cell Activation Determines Transgene Expressionin Vitroandin Vivo
- 10 June 2000
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 11 (9), 1303-1311
- https://doi.org/10.1089/10430340050032401
Abstract
T lymphocytes, regardless of their specificity, are considered key targets for genetic modification in the treatment of inherited or acquired human diseases. In this study, we generated Lewis T cell lines specific for Dark Agouti rat alloantigens and tested the potential of allospecific T lymphocytes as carriers of genes encoding therapeutic proteins in transplantation gene therapy. These allospecific T lymphocytes were successfully, stably transduced with enhanced green fluorescent protein (EGFP) by an Mo-MuLV-based retrovirus vector. A novel gene delivery protocol was utilized, resulting in nearly 100% EGFP-expressing T cells. This approach enabled tracking of allospecific transduced T cells in vivo and illustrates their transgene production by fluorometric determination after ex vivo isolation. Quantitation of EGFP transgene expression was used to determine the influence of T cell receptor-specific activation on transgene regulation. A strict positive correlation between activation state and expression level was detected in vitro and in vivo. The activation-induced increase in transgene expression could be blocked by interference with T cell activation signaling pathways by cyclosporin A, anti-CD4 MAb, or CTLA4-Ig. These data provide strong evidence that direct or indirect effects caused by activation-induced transcription factors are crucial in transgene upregulation. Allospecific activation in spleens, lymph nodes, and transplanted grafts can be considered as antigen-specific targeting strategy. This activation might be useful in expressing therapeutic proteins such as TGF-β or IL-10 specific to these sites. T lymphocyte priming and activation might be prevented or altered by modification of the local microenvironments, thereby exerting a therapeutic influence on acute and chronic graft rejection processes.Keywords
This publication has 35 references indexed in Scilit:
- Costimulation of Transduced T Lymphocytes via T Cell Receptor-CD3 Complex and CD28 Leads to Increased Transcription of Integrated RetrovirusHuman Gene Therapy, 1999
- Improvement of Gene Transduction Efficiency in T Lymphocytes Using Retroviral VectorsHuman Gene Therapy, 1999
- Green Fluorescent Protein as a Selectable Marker of Fibronectin-Facilitated Retroviral Gene Transfer in Primary Human T LymphocytesHuman Gene Therapy, 1999
- High-Resolution Analysis of Cytosine Methylation in the 5′ Long Terminal Repeat of Retroviral VectorsHuman Gene Therapy, 1998
- Prostaglandin E2 Up-regulates HIV-1 Long Terminal Repeat-driven Gene Activity in T Cells via NF-κB-dependent and -Independent Signaling PathwaysPublished by Elsevier ,1998
- T Cell Activation Modulates Retrovirus-Mediated Gene ExpressionHuman Gene Therapy, 1998
- Prevention of adoptively transferred diabetes in nonobese diabetic mice with IL-10-transduced islet-specific Th1 lymphocytes. A gene therapy model for autoimmune diabetes.JCI Insight, 1996
- Retroviral vectors for persistent expression in vivoCurrent Opinion in Biotechnology, 1992
- An in Vivo Model of Somatic Cell Gene Therapy for Human Severe Combined ImmunodeficiencyScience, 1991
- The rapid isolation of clonable antigen‐specific T lymphocyte lines capable of mediating autoimmune encephalomyelitisEuropean Journal of Immunology, 1981